Goldman Sachs Group Inc Atea Pharmaceuticals, Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 300,928 shares of AVIR stock, worth $959,960. This represents 0.0% of its overall portfolio holdings.
Number of Shares
300,928
Previous 221,342
35.96%
Holding current value
$959,960
Previous $732,000
37.7%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding AVIR
# of Institutions
112Shares Held
52.4MCall Options Held
900Put Options Held
126K-
Black Rock Inc. New York, NY9.12MShares$29.1 Million0.0% of portfolio
-
Bml Capital Management, LLC Zionsville, IN6.65MShares$21.2 Million13.11% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5.44MShares$17.4 Million0.79% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.85MShares$15.5 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA4.61MShares$14.7 Million1.31% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $266M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...